 BOTHELL, Wash., Aug. 23, 2021 GLOBE NEWSWIRE -- Athira Pharma, Inc. NASDAQ: ATHA, a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials ERPs by using ERP P300 in Alzheimers drug development, and the utility of ERP P300 in Athiras Phase 1 clinical trials, at the Annual Biomarkers for Alzheimers Disease Summit taking place virtually August 24-26, 2021. 